Company profile
BioSyent Inc.
OTC: BIOYF · Healthcare · Medical - Pharmaceuticals
Canadian filerHQ Mississauga, ONReports USD
#501 of 1,418 Healthcare companies by revenue67th-percentile growth
EA Score
83B+FH 90DQ —GM 69SS 71
v0.1 · 45/100 weight · provisional
↑ return on assets, operating margin · ↓ disclosure history, 3-yr revenue growth
Methodology →Revenue TTM
$40.3M
Rev growth YoY (TTM)
+42.5%
Net income (FY)
$6.4M
Employees
711
as of 2026-08-18
Market cap
$121.7M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$30.8M43.0M CAD2025
Net income$6.4M9.0M CAD2025
Operating income$8.1M11.3M CAD2025
Total assets$36.0M49.4M CAD2025
Liabilities$5.8M8.0M CAD2025
Equity$30.2M41.4M CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is BioSyent Inc.’s revenue?
BioSyent Inc. booked $30.8M in FY2025 revenue, growing 20% year over year — faster than most Healthcare companies we track, at a 20.9% net margin.
Peers · Healthcare
Verastem, Inc.49DFoghorn Therapeutics Inc.47DScripsAmerica, Inc.——STRATA Skin Sciences, Inc.52DYourWay Cannabis Brands Inc.——Synergy CHC Corp.35DKey facts
CEORené C. Goehrum
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersMississauga, ON
ExchangeOTC: BIOYF
Employees711
IPO date2012-02-22
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.